Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPV.DCVax
2022-502930-25-00Phase 2Completed
- Sponsor
- Gustave Roussy
- Start
- Jul 2023
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of DCVax-L in oropharyngeal squamous cell carcinoma (OPSCC) (2 arms), sponsored by Gustave Roussy. Primary endpoints: Safety of HPV.DCVax and Immunogenicity of HPV.DCVax. Started Jul 2023; status: completed.
02
Drugs
DCVax-L
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on 2022-502930-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502930-25-00.